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Purpose: Although there is no clinical evidence of nephrotoxicity with the volatile 
anesthetics currently used in general anesthesia, a better agent should be needed in 
terms of preserving postoperative renal function in living kidney donors who have 
only single remaining kidney. The purpose of the current retrospective, single-cen-
ter study was to evaluate and compare renal function of living kidney donors after 
nephrectomy under either sevoflurane or desflurane anesthesia. Materials and 
Methods: From January 2006 through December 2011, a total of 228 donors un-
dergoing video assisted minilaparotomy surgery nephrectomy for kidney donation 
were retrospectively enrolled in the current study. The donors were categorized 
into a sevoflurane group or desflurane group based on the type of volatile anesthet-
ic used. We collected laboratory data from the patients preoperatively, immediately 
after the operation, on the first postoperative day and on the third postoperative 
day. We also compared renal function of the kidney donors after donor nephrecto-
my by comparing creatinine level and estimated glomerular filtration rate (eGFR). 
Results: The decrease in renal function after surgery in both groups was the most 
prominent on the first postoperative day. There were no significant differences be-
tween the two groups in postoperative changes of creatinine or eGFR. Conclusion: 
Sevoflurane and desflurane can be used safely as volatile anesthetics in donors un-
dergoing nephrectomy.
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INTRODUCTION
The nobility of donors and the belief that donation will not harm the donor have 
increased the frequency of kidney donation from living donors.1 Although the ex-
isting body of evidence suggests that living kidney donors have medical outcomes 
similar to those in the general population,2 several reports have demonstrated the 
potential risks of developing hypertension, proteinuria, and end stage renal disease 
(ESRD).1,3 In addition, many institutes have expanded the selection criteria for do-
nors, accepting donors with well-controlled hypertension and advanced age due to 
increasing number of patients reaching ESRD and the improvement in clinical 
outcomes of renal allograft.4 For these reasons, all efforts should be concentrated 
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ing video-assisted minilaparotomy surgery (VAMS).21 The 
patients were managed intraoperatively using the standard 
anesthesia protocol for our institution. 
 
Anesthesia protocol
Upon arrival at the operating room, the donors were moni-
tored with pulse oximetry, noninvasive arterial blood pres-
sure (BP), electrocardiography, and capnography. Anesthe-
sia was induced with either intravenous propofol (2 mg/kg) 
or thiopental (3-5 mg/kg) and a continuous infusion of remi-
fentanil (0.1-0.15 μg·kg-1·min-1). Rocuronium (0.6 mg/kg) 
was given to achieve adequate muscle relaxation before en-
dotracheal intubation. After endotracheal intubation, an ad-
ditional intravenous catheter was inserted into the external 
jugular vein or antecubital vein. For anesthesia maintenance, 
the volatile anesthetic chosen by the attending anesthesiolo-
gists was carefully titrated to maintain an end-tidal concen-
tration of 1-1.5 minimal alveolar concentration (MAC) with 
50% oxygen in air mixture. Continuous infusion of remi-
fentanil was adjusted to maintain intraoperative BP and 
heart rate within 20% of the preoperative values. Arterial hy-
potension during anesthesia maintenance was treated by ad-
justment of anesthesia level and fluid therapy instead of us-
ing vasopressor. The amount of administered fluid was 
initially 10 mL/kg/hour and was adjusted to maintain an ad-
equate urine output of greater than 100 mL/hour. Mannitol 
(0.5 g/kg) was routinely administered before manipulation 
of the kidney. Inadequate urine output was treated with 300-
500 mL of loading fluid or intravenous administration of 
5-10 mg furosemide when necessary. Heparin (70 unit/kg) 
was given intravenously before vessel ligation. After re-
moval of the kidney, the amount of administered fluid was 
maintained minimally, and protamine sulfate (0.7 mg/kg) 
was given intravenously. At the end of the operation, the in-
haled anesthetic was discontinued, and the neuromuscular 
block was reversed with intravenous administration of 0.2 
mg glycopyrrolate and 1 mg neostigmine. After endotracheal 
extubation, the donors were transferred to the post anesthesia 
care unit (PACU). For postoperative pain control, intrave-
nous patient-controlled analgesia, using fentanyl without 
non-steroidal anti-inflammatory drug, was administered.
Data collection
Medical records were reviewed and laboratory data were 
collected for investigation. The donors enrolled in the cur-
rent study were assigned to either the desflurane or sevoflu-
rane group based on the volatile anesthetic used.
on ensuring the safety of patients and preserving the func-
tion of the remaining kidney during anesthesia maintenance. 
However, most studies have focused on the anesthesia and 
intraoperative management of the recipients rather those of 
the donors.5-8 Therefore, the adequacy of current anesthetic 
management for donors should be evaluated as well. 
Volatile anesthetics have been frequently used for general 
anesthesia for nephrectomy of kidney donor.9 The typical 
volatile anesthetics commonly used nowadays are sevoflu-
rane and desflurane.10-13 Sevoflurane has the potential to ad-
versely affect the kidney function because an inorganic fluo-
ride ion from the defluorination of sevoflurane and com-
pound A from reaction with carbon dioxide absorbent are 
associated with nephrotoxicity.14,15 On the other hand, des-
flurane is extremely resistant to defluorination, and it does 
not appear to be nephrotoxic.16 Although any nephrotoxic 
effect of sevoflurane in human has not yet been proven, this 
issue is still subject to debate due to many literatures related 
to sevoflurane induced nephrotoxicity.14,15,17-19 Recently, a 
study performed in living donor hepatectomy demonstrated 
better postoperative kidney function with desflurane than 
with sevoflurane.20
Although there is no clinical evidence of nephrotoxicity 
with the volatile anesthetics currently used in general anes-
thesia, a better agent should be chosen in terms of preserv-
ing postoperative kidney function in living donors who have 
only a single kidney remaining. The purpose of the current 
retrospective, single-center study was to evaluate and com-
pare kidney function of living donors after nephrectomy un-
der either sevoflurane or desflurane anesthesia.
MATERIALS AND METHODS
　　　
Study population
From January 2006 through December 2011, a total of 228 
donors undergoing nephrectomy for kidney donation under 
sevoflurane or desflurane anesthesia were retrospectively 
enrolled in the current study. Patients undergoing periopera-
tive transfusion or re-operation were excluded. All the do-
nors underwent preoperative evaluation including a complete 
history, physical examination, and laboratory assessment to 
rule out diseases of major organs, infections, and other sys-
temic illness. Abdominal-pelvic computed tomography with 
angiography was performed to investigate the anatomy of 
the kidney and vascular structures before surgery. 
The nephrectomies were performed by two urologists us-
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cago, IL, USA). Continuous data were presented as mean 
(standard deviation) and were analyzed using the indepen-
dent Student t-test or Mann-Whitney U test. Categorical 
data were presented as numbers (percentages) and were ana-
lyzed using the chi-square test or Fisher’s exact test. p<0.05 
was considered statistically significant. 
 
RESULTS
 
Among the 228 donors enrolled in the study, six donors 
(one from the desflurane group and five from the sevoflu-
rane group) were excluded because of red blood cell trans-
fusions during the perioperative period. As a result, we ulti-
mately investigated 113 donors in the desflurane group and 
109 donors in the sevoflurane group. There were no differ-
ences in donor characteristics and preoperative laboratory 
data between the two groups (Table 1). 
Table 2 shows the intraoperative and postoperative data 
of both groups. The surgical time of the desflurane group 
was significantly shorter than that of the sevoflurane group 
(p=0.019), but there was no significant difference in anes-
thetic time between the two groups (p=0.163). Duration of 
PACU stay of the desflurane group was significantly short-
er than that of the sevoflurane group (55.6±21.9 min vs. 
68.0±30.2 min, p=0.001). However, postoperative hospital 
stay did not differ between the two groups. 
Patient characteristics including gender, age at operation, 
height, weight, body mass index, and medical history were 
recorded. Intraoperative data included surgical and anesthet-
ic times, administered fluids, intraoperative blood loss, urine 
output, intraoperative transfusion of blood products, and use 
of furosemide. Duration of stay in the PACU, duration of 
postoperative hospital stay, and postoperative transfusion of 
blood products were assessed as postoperative data. We col-
lected laboratory data from the patients preoperatively, im-
mediately after the operation, on the first postoperative day, 
and on the third postoperative day. The laboratory data in-
cluded hemoglobin, hematocrit, platelet count, prothrombin 
time, albumin, aspartate aminotransferase, alanine amino-
transferase, blood urea nitrogen, creatinine (Cr), and estimated 
glomerular filtration rate (eGFR). Estimated GFR was calcu-
lated using the Modification of Diet in Renal Disease formula 
with age, gender, race, and serum creatinine as variables.22 
The following variables were used to compare kidney func-
tion before and after surgery and were calculated from the 
data obtained: ΔCreatinine (value of postoperative Cr-value of 
preoperative Cr), ΔeGFR (value of postoperative eGFR-value 
of preoperative eGFR), ΔCreatinine% (ΔCreatinine/value of 
preoperative Cr), and ΔeGFR% (ΔeGFR/value of preopera-
tive eGFR).
Statistical analysis
We analyzed the data with SPSS version 18 (SPSS Inc., Chi-
Table 1. Patient Characteristics and Preoperative Laboratory Data
Parameter Desflurane (n=113) Sevoflurane (n=109) p value
Patient characteristic
    Age (yrs)     39.8±11.3     40.1±10.7 0.842
    Gender (M/F) 47 (42)/66 (58) 58 (53)/51 (47) 0.083
    Height (cm) 164.3±9.0 165.4±8.7 0.365
    Weight (kg)     62.9±10.3     65.3±10.0 0.073
    Hypertension history 1 (0.9) 3 (3) 0.296
Body mass index (kg/m2)   23.2±2.4   23.8±2.4 0.057
Preoperative laboratory data
    Hemoglobin (g/dL)   13.9±1.5   14.0±1.5 0.616
    Hematocrit (%)   41.5±4.0   41.1±4.1 0.374
    Platelet (109/L)   257.1±57.0   256.8±60.8 0.974
    Prothrombin time (s)   10.9±0.8   10.9±0.8 0.506
    Albumin (mg/dL)     4.6±0.3     4.6±0.3 0.355
    AST (IU/L)   18.4±7.5   18.9±5.3 0.597
    ALT (IU/L)     18.5±12.8     20.8±13.3 0.202
    Blood urea nitrogen (mg/dL)   12.5±5.3   12.6±3.0 0.799
    Creatinine (mg/dL)     0.8±0.2     0.9±0.1 0.076
    eGFR (mL/min)     95.1±15.2     94.7±13.5 0.829
AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; SD, standard deviation.
Data are presented as mean±SD or number of patients (%).
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Sevoflurane has many advantages such as pleasant odor, 
no pungency, and bronchodilating effect, while desflurane 
does not have these qualities.10 However, the concern about 
the nephrotoxicity of sevoflurane exists still.19 The issues of 
nephrotoxicity related to sevoflurane use are based not only 
on its fluoride metabolite but also on compound A.10,23 Early 
reports of fluoride-associated nephrotoxicity from the metab-
olism of volatile anesthetics focused on methoxyflurane and 
enflurane, and the toxic threshold of inorganic fluoride asso-
ciated with nephrotoxicity was found to be 50 µmol/L.24,25 
Previous investigations of sevoflurane metabolism demon-
strated that a fluoride ion concentration greater than 50 µmol/
L could be observed even though sevoflurane was used dur-
ing operations of average duration. Still, no renal toxicity was 
demonstrated.14,26 Compound A is the other concerned me-
tabolite associated with the use of sevoflurane. Compound A, 
Figs. 1 and 2 compare the results of postoperative kidney 
function tests between the two groups. The decrease in kid-
ney function after surgery was the most prominent on the 
first postoperative day for both groups. There were no sig-
nificant differences in the postoperative changes in creati-
nine and eGFR between the two groups. 
DISCUSSION
In this study, we compared the postoperative kidney func-
tion of living donors according to the type of volatile anes-
thetic used during nephrectomy. The similar outcomes ob-
served between the sevoflurane group and the desflurane 
group suggest that the choice of volatile anesthetic did not 
affect residual kidney function after donor nephrectomy. 
Table 2. Intraoperative and Postoperative Data
Parameter Desflurane (n=113) Sevoflurane (n=109) p value
Surgical time (min)   187.8±48.2   202.8±46.4 0.019
Anesthetic time (min)   231.1±51.3   240.5±48.1 0.163
Administered fluid (mL)   2406.7±798.4   2401.2±874.7 0.961
Estimated blood loss (mL)       99.6±131.3     110.0±168.1 0.578
Urine output (mL·kg-1·h-1)     1.7±1.1     2.0±1.3 0.243
Furosemide use (n) 14 (12) 17 (16) 0.491
PACU duration (min)     55.6±21.9     68.0±30.2 0.001
Postoperative hospital stay (d)     5.8±1.3     5.9±1.2 0.622
PACU, post anesthesia care unit; SD, standard deviation.
Data are presented as mean±SD or number of patients (%).
Fig. 1. Comparisons of ΔCreatinine and ΔCreatinine% between the desflurane group and sevoflurane group. The box contains the middle 50% of the data, 
and the line in the box indicates the median value of the data. The upper edge of the box represents the 75th percentile of the data set, and the lower edge 
represents the 25th percentile. The range of the middle two quartiles means the inter-quartile range. The ends of the vertical lines represent the minimum 
and maximum values of the data set unless outliers do not exist, in which case the vertical lines extend to a maximum of 1.5 times the inter-quartile range. 
Any data that does not exist between the vertical lines should be marked as an outlier with a circle. ΔCreatinine, value of postoperative creatinine-value of 
preoperative creatinine; ΔCreatinine%, ΔCreatinine/value of preoperative creatinine test; A, value immediately after operation-preoperative value; B, value 
on the first postoperative day-preoperative value; C, value on the third postoperative day-preoperative value.
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Intrarenal metabolism of methoxyflurane and subsequent in-
trarenal production of fluoride ion are considered to be a sig-
nificant cause of the nephrotoxic effects of methoxyflurane. 
The possibility of nephrotoxicity with sevoflurane is counter-
balance by its minimal intrarenal metabolism.27 Furthermore, 
several studies, especially a randomized study in patients 
with pre-existing renal disease, have failed to demonstrate 
the existence of nephrotoxic effects associated with com-
pound A in humans.28,29 
The difference in surgical technique for living donor ne-
phrectomy can affect postoperative kidney function. A pre-
vious study showed that the decline in kidney function in 
laparoscopic donor nephrectomy was significantly greater 
than that in open donor nephrectomy because of pneumo-
peritoneum and prolonged anesthesia use.30 The VAMS ap-
proach is a safe and minimally invasive technique for donor 
nephrectomy, with favorable outcomes including less post-
operative pain and a quick recovery. It has been performed 
over the years in our institute.21 Therefore, the impact of 
surgical technique on postoperative outcome in this study 
was thought to be negligible.
Intraoperative data from this study showed that the sevo-
flurane group had a longer surgical time, whereas the anes-
thetic times of both groups were similar. The nephrotoxicity 
of sevoflurane is closely correlated with the duration of its 
exposure in terms of fluoride and compound A.25,31 In this 
study, the duration of exposure of volatile anesthetics was 
similar between the two groups, given the lack of differ-
or fluoromethyl-2-2-difluoro-1-(trifluoromethyl) vinyl ether, 
is formed during the interaction of sevoflurane with carbon 
dioxide absorbents, and it has been shown to be a dose-de-
pendent nephrotoxin in rats.15 In contrast, desflurane does 
not appear to be nephrotoxic because of its resistance to de-
fluorination and no increase in serum fluoride concentration 
after exposure to desflurane.10 
Previous findings in comparison of kidney function be-
tween patients receiving sevoflurane or desflurane were not 
consistent. A study which compared the effects of sevoflu-
rane and desflurane on kidney function after living donor 
hepatectomy demonstrated better postoperative kidney func-
tion with desflurane than with sevoflurane.20 However, an-
other study on postoperative renal responses following the 
use of desflurane, sevoflurane, or propofol reported that 
changes in postoperative kidney function were not affected 
by the choice of anesthetic.18 Many conditions including the 
extent of surgical stress, surgical site, preoperative kidney 
function, and intraoperative hemodynamics can affect post-
operative kidney function.18,20 Differences in these condi-
tions could potentially explain for the inconsistent results of 
studies looking at postoperative kidney function. The safety 
of sevoflurane with regard to kidney function in this study 
may be the result of a rapid decline in plasma fluoride con-
centration due to its lower availability because of a faster 
washout.19 Also, the site of metabolism is an important fac-
tor in fluoride-induced toxicity. That is, intrarenal metabo-
lism of inhaled anesthetics contributes to nephrotoxic effects. 
Fig. 2. Comparisons of ΔeGFR and ΔeGFR% between the desflurane group and sevoflurane group. The box contains the middle 50% of the data, and the line 
in the box indicates the median value of the data. The upper edge of the box represents the 75th percentile of the data set, and the lower edge represents 
the 25th percentile. The range of the middle two quartiles means the inter-quartile range. The ends of the vertical lines represent the minimum and maximum 
values of the data set unless outliers do not exist, in which case the vertical lines extend to a maximum of 1.5 times the inter-quartile range. Any data that 
does not exist between the vertical lines should be marked as an outlier with a circle. ΔeGFR, value of postoperative estimated glomerular filtration rate-val-
ue of preoperative estimated glomerular filtration rate; ΔeGFR%, eGFR/value of preoperative estimated glomerular filtration rate; A, value immediately after 
operation-preoperative value; B, value on the first postoperative day-preoperative value; C, value on the third postoperative day-preoperative value.
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20. Ko JS, Gwak MS, Choi SJ, Yang M, Kim MJ, Lee JY, et al. The 
effects of desflurane and sevoflurane on hepatic and renal func-
tions after right hepatectomy in living donors*. Transpl Int 2010; 
23:736-44. 
21. Kim SI, Rha KH, Lee JH, Kim HJ, Kwon KI, Kim YS, et al. Fa-
vorable outcomes among recipients of living-donor nephrectomy 
using video-assisted minilaparotomy. Transplantation 2004;77: 
1725-8.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A 
more accurate method to estimate glomerular filtration rate from 
serum creatinine: a new prediction equation. Modification of Diet 
in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
23. Fang ZX, Kandel L, Laster MJ, Ionescu P, Eger EI. Factors affect-
ing production of compound A from the interaction of sevoflurane 
with Baralyme and soda lime. Anesth Analg 1996;82:775-81.
24. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity. A study 
of dose response in man. JAMA 1973;225:1611-6.
25. Mazze RI, Calverley RK, Smith NT. Inorganic fluoride nephro-
ence in anesthetic times. The variables related to postopera-
tive kidney function of the sevoflurane group were compa-
rable to those of the desflurane group.
This study has several limitations. First, since the design 
of this study was retrospective, an additional prospective 
study is required. In this study, surgical technique and anes-
thesia protocol were applied equally to all of the donors, and 
there were a sufficient number of donors enrolled. In pro-
spective studies of donors, a higher level of ethics and safety 
are required. Thus, sufficient evidence should be obtained 
through companion papers and retrospective studies before 
performing a prospective study. Second, we investigated 
only traditional parameters of kidney function. Biomarkers 
such as neutrophil gelatinase-associated lipocalin, cystatin 
C, and interleukin-18 have been proposed for early detec-
tion of acute kidney injury.32 Because of widely varying di-
agnostic characteristics reported from previous studies and 
the necessary identification of significant factors that may 
confuse biomarker interpretation in the perioperative peri-
od, these biomarkers are not yet applicable for use in rou-
tine clinical practice.33 Third, the dose of sevoflurane and 
desflurane used for anesthesia maintenance might not be 
equipotent because the end-tidal concentration during anes-
thesia could not be maintained with identical MAC values 
in both groups.
The results of this study revealed comparable postopera-
tive kidney function with sevoflurane or desflurane anes-
thesia use in living donors undergoing VAMS nephrecto-
my. It is concluded that sevoflurane and desflurane can be 
used safely as volatile anesthetics in donors undergoing ne-
phrectomy.
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